Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer

Clinical Breast Cancer

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Boccardo, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Anastrozole; Endocrine therapy; Exemestane; Letrozole

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; HORMONE RECEPTOR; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADVANCED CANCER; ARTHROPATHY; BONE DISEASE; BREAST CANCER; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; ENDOMETRIUM CANCER; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; PATIENT SELECTION; POSTMENOPAUSE; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM;

EID: 4644247253     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2004.s.009     Document Type: Article

References (15)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-1467.
2. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93:684-690.
3. Goss P Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin Oncol 2001; 19:881-894.
4. Stewart HJ, Forrest AP, Everington D, et al. Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996; 74:297-299.
5. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996; 88:1828-1833.
6. Sacco M, Valentini M, Belfiglio M, et al. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01. J Clin Oncol 2003; 21:2276-2281.
7. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131-2139.
8. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98:1802-1810.
9. Winer, EP Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002;20:3317-3327.
10. Boccardo F Rubagotti A, Amoroso D, et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian Cooperative Study. J Clin Oncol 2001; 19:4209-4215.
11. Boccardo E Rubagotti A, Amoroso D. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003; 82:S6 (Abstract #3).
12. Boccardo F, Rubagotti A, Amoroso D. Tamoxifen (TMX) followed by an aromatase inhibitor (AI) in early breast cancer. A pooled analysis of two consecutive trials. Presented at: the 8th Nottingham International Breast Cancer Conference. September 17-19, 2003; Nottingham, United Kingdom.
13. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-1092.
14. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-1802.
15. Howell A. Effect of anastrozole on bone mineral density: 2-year results of the 'arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) trial. Breast Cancer Res Treat 2003; 82:S27 (Abstract #129).